Smart pH-responsive nanomedicines for disease therapy
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Currently nanomedicines are the focus of attention from researchers and clinicians because of the successes of lipid-nanoparticles-based COVID-19 vaccines. Nanoparticles improve existing treatments by providing a number of advantages including protection of cargo molecules from external stresses, delivery of drugs to target tissues, and sustained drug release. To prevent premature release-related side effects, stable drug loading in nanoformulations is required, but the increased stability of the formulation could also lead to a poor drug-release profile at the target sites. Thus, researchers have exploited differences in a range of properties (e.g., enzyme levels, pH, levels of reduced glutathione, and reactive oxygen species) between non-target and target sites for site-specific release of drugs. Among these environmental stimuli, pH gradients have been widely used to design novel, responsive nanoparticles. In this review, we assess drug delivery based on pH-responsive nanoparticles at the levels of tissues (tumor microenvironment, pH ~ 6.5) and of intracellular compartments (endosome and lysosome, pH 4.5–6.5). Upon exposure to these pH stimuli, pH-responsive nanoparticles respond with physicochemical changes to their material structure and surface characteristics. These changes include swelling, dissociation, or surface charge switching, in a manner that favors drug release at the target site (the tumor microenvironment region and the cytosol followed by endosomal escape) rather than the surrounding tissues. Lastly, we consider the challenges involved in the development of pH-responsive nanomedicines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., Wei, R., Fleming, M. D., Schreiber, S. L., & Cantley, L. C. (2008) · Nature · doi:10.1038/nature06734 · Cited by 2,820 · cited 1×
“The oncogenic metabolism results in the accumulation of a large amount of lactic acid along with excess protons and carbon dioxide (termed the Warburg effect) (Christofk et al. 2008).”
BackgroundDesign and development of polymers for gene delivery
Pack, D. W., Hoffman, A. S., Pun, S., & Stayton, P. S. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1775 · Cited by 2,568 · cited 4×
“, hydrolysis, enzyme-mediated degradation, and low pH), especially in endosomes or lysosomes (Pack et al. 2005; Torchilin 2008; Kanasty et al. 2013; Zhao et al. 2014; Qin et al. 2019; Chaudhary et al. 2021; Damase et al. 2021).”
BackgroundInfluentialDelivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555 · cited 5×
“In many cases, target sites and target molecules for drugs are usually located in the intracellular regions (Pack et al. 2005; Torchilin 2008; Kanasty et al. 2013; Zhao et al. 2014; Qin et al. 2019; Chaudhary et al. 2021; Damase et al. 2021).”
BackgroundInfluentialMechanism of oligonucleotide release from cationic liposomes.
Zelphati, O., & Szoka, F. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11493 · Cited by 634 · cited 1×
“Likewise, particles (especially liposomes) assembled from lipids or amphiphilic materials may also allow the loaded drug to enter the cytoplasm by fusion of the nanoparticle membrane (e.g., the phospholipid bilayer of a liposome) with the endosomal membrane (Zelphati and Szoka 1996).”
BackgroundmRNA vaccine delivery using lipid nanoparticles
Reichmuth, A. M., Oberli, M. A., Jaklenec, A., Langer, R., & Blankschtein, D. (2016) · Therapeutic Delivery · doi:10.4155/tde-2016-0006 · Cited by 624
Li, W. (2004) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.10.041 · Cited by 588
pH-responsive polymer nanoparticles for drug delivery
Deirram, N., Zhang, C., Kermaniyan, S. S., Johnston, A. P. R., & Such, G. K. (2019) · Macromolecular Rapid Communications · doi:10.1002/marc.201800917 · Cited by 531
Liposomes for use in gene delivery
Balazs, D. A., & Godbey, W. (2011) · Journal of Drug Delivery · doi:10.1155/2011/326497 · Cited by 441
Sebastiani, F., Yanez Arteta, M., Lerche, M., Porcar, L., Lang, C., Bragg, R. A., Elmore, C. S., Krishnamurthy, V. R., Russell, R. A., Darwish, T., et al. (2021) · ACS Nano · doi:10.1021/acsnano.0c10064 · Cited by 409
Cited by
Li, H., Li, B., Lv, D., Li, W., Lu, Y., & Luo, G. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114778 · Cited by 142
The Future of Tissue-Targeted Lipid Nanoparticle-Mediated Nucleic Acid Delivery
Kularatne, R. N., Crist, R. M., & Stern, S. T. (2022) · Pharmaceuticals · doi:10.3390/ph15070897 · Cited by 109
Rampedi, P. N., Ogunrombi, M. O., & Adeleke, O. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060712 · Cited by 15
“Furthermore, the stability of drugs within the acidic environment of the stomach or susceptibility to enzymatic degradation can hinder optimal drug absorption and pharmacological effect [206].”
Background
Metadata
- Authors
- Shinn, J., Kwon, N., Lee, S. A., & Lee, Y.
- Venue
- Journal of Pharmaceutical Investigation
- Published
- 2022-05-09
- Volume
- 52
- Issue
- 4
- Pages
- 427-441
- ISSN
- 2093-5552 (ISSN-L)
- 2093-6214
- OpenAlex
- W4229449460
- Cited by
- 131
- References
- 13
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Smart pH-responsive nanomedicines for disease therapy. https://app.cochat.ai/papers/10.1007/s40005-022-00573-z
- The paper
- Shinn, J., Kwon, N., Lee, S. A., & Lee, Y. (2022). Smart pH-responsive nanomedicines for disease therapy. Journal of Pharmaceutical Investigation. https://doi.org/10.1007/s40005-022-00573-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.